Toxicity comparison of chlorinated and brominated dibenzo- p-dioxins and dibenzofurans in industrial source samples by HRGC/HRMS and enzyme immunoassay

Limited information is available on the applicability of polychlorinated dibenzo- p-dioxin/furan (PCDD/F) toxicity assays to their brominated counterparts: polybrominated dibenzo- p-dioxins/furans (PBDDs/Fs). We estimated the toxicity of mixtures of chlorinated, brominated, and mixed bromochloro-dio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Environment international 2010-04, Vol.36 (3), p.247-253
Hauptverfasser: Samara, Fatin, Wyrzykowska, Barbara, Tabor, Dennis, Touati, Dahman, Gullett, Brian K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Limited information is available on the applicability of polychlorinated dibenzo- p-dioxin/furan (PCDD/F) toxicity assays to their brominated counterparts: polybrominated dibenzo- p-dioxins/furans (PBDDs/Fs). We estimated the toxicity of mixtures of chlorinated, brominated, and mixed bromochloro-dioxins and -furan (PBCDDs/Fs) laboratory standards using a chemically-activated luciferase gene expression cell bioassay (CALUX). The relative effects potency (REP) values obtained were comparable to the World Health Organization (WHO) toxic equivalency factors (TEFs) and in agreement with the concept of additive congener toxicity of mixtures of dioxins and furans. Enzyme immunoassay (EIA)-based toxic equivalents (TEQs), however, showed overestimation for PCDDs/Fs (0–4 orders of magnitudes higher) and underestimation for PBDDs/Fs (0–1 orders of magnitude lower) when compared to high resolution gas chromatography/high resolution mass spectrometry (HRGC/HRMS)-based TEQ calculation (using WHO TEFs) in samples from an industrial source line. No correlation was found between the EIA and the HRGC/HRMS data, which could be attributed to differences in homologue-specific cross-reactivity responses, sample matrix type, and presence of other compounds competing for antibody binding in the immunoassay.
ISSN:0160-4120
1873-6750
DOI:10.1016/j.envint.2009.12.005